Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 7 |
List of Tables | 7 | 1 |
List of Figures | 8 | 1 |
Introduction | 9 | 1 |
Global Markets Direct Report Coverage | 9 | 1 |
Leishmaniasis (Kala-Azar) Overview | 10 | 1 |
Therapeutics Development | 11 | 2 |
Pipeline Products for Leishmaniasis (Kala-Azar) Overview | 11 | 1 |
Pipeline Products for Leishmaniasis (Kala-Azar) Comparative Analysis | 12 | 1 |
Leishmaniasis (Kala-Azar) Therapeutics under Development by Companies | 13 | 2 |
Leishmaniasis (Kala-Azar) Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
Leishmaniasis (Kala-Azar) Pipeline Products Glance | 16 | 4 |
Late Stage Products | 16 | 1 |
Clinical Stage Products | 17 | 1 |
Early Stage Products | 18 | 1 |
Unknown Stage Products | 19 | 1 |
Leishmaniasis (Kala-Azar) Products under Development by Companies | 20 | 1 |
Leishmaniasis (Kala-Azar) Products under Investigation by Universities/Institutes | 21 | 1 |
Leishmaniasis (Kala-Azar) Companies Involved in Therapeutics Development | 22 | 9 |
Advinus Therapeutics Ltd | 22 | 1 |
BioLingus AG | 23 | 1 |
iCo Therapeutics Inc. | 24 | 1 |
Laboratorios LETI S.L. | 25 | 1 |
ManRos Therapeutics | 26 | 1 |
Matinas BioPharma Holdings, Inc. | 27 | 1 |
Nanomerics Ltd | 28 | 1 |
Novartis AG | 29 | 1 |
Oblita Therapeutics BVBA | 30 | 1 |
Leishmaniasis (Kala-Azar) Therapeutics Assessment | 31 | 10 |
Assessment by Monotherapy Products | 31 | 1 |
Assessment by Combination Products | 32 | 1 |
Assessment by Target | 33 | 2 |
Assessment by Mechanism of Action | 35 | 2 |
Assessment by Route of Administration | 37 | 2 |
Assessment by Molecule Type | 39 | 2 |
Drug Profiles | 41 | 49 |
(gentamicin sulfate + paromomycin sulfate) Drug Profile | 41 | 1 |
18-MC Drug Profile | 42 | 1 |
amphotericin B Drug Profile | 43 | 2 |
amphotericin B Drug Profile | 45 | 1 |
amphotericin B Drug Profile | 46 | 3 |
amphotericin B Drug Profile | 49 | 1 |
Amphotericin B sodium Drug Profile | 50 | 2 |
candicidin Drug Profile | 52 | 1 |
CDRI-99288 Drug Profile | 53 | 1 |
D-121 Drug Profile | 54 | 2 |
Drugs for Leishmaniasis and Trypanosomiasis Drug Profile | 56 | 1 |
GNF-6702 Drug Profile | 57 | 1 |
hypoestoxide Drug Profile | 58 | 1 |
interferon gamma Drug Profile | 59 | 1 |
KVH-14 Drug Profile | 60 | 1 |
leishmaniasis vaccine Drug Profile | 61 | 1 |
leishmaniasis vaccine Drug Profile | 62 | 1 |
leishmaniasis vaccine Drug Profile | 63 | 1 |
leishmaniasis vaccine Drug Profile | 64 | 1 |
leishmaniasis vaccine 2 Drug Profile | 65 | 1 |
NPC-1161B Drug Profile | 66 | 1 |
P-MAPA Drug Profile | 67 | 2 |
Peptides for Infectious Diseases Drug Profile | 69 | 1 |
S-010269 Drug Profile | 70 | 1 |
SJL-01 Drug Profile | 71 | 1 |
Small Molecule for Leishmaniasis Drug Profile | 72 | 1 |
Small Molecule for Leishmaniasis Drug Profile | 73 | 1 |
Small Molecule for Visceral Leishmaniasis Drug Profile | 74 | 1 |
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis Drug Profile | 75 | 1 |
Small Molecules for Infectious Diseases Drug Profile | 76 | 1 |
Small Molecules for Infectious Diseases Drug Profile | 77 | 1 |
Small Molecules for Leishmaniasis Drug Profile | 78 | 1 |
Small Molecules for Leishmaniasis Drug Profile | 79 | 1 |
Small Molecules for Visceral Leishmaniasis Drug Profile | 80 | 1 |
Small Molecules for Visceral Leishmaniasis Drug Profile | 81 | 1 |
Small Molecules to Block LHR1 for Leishmaniasis Drug Profile | 82 | 1 |
Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases Drug Profile | 83 | 1 |
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease and Leishmaniasis Drug Profile | 84 | 1 |
Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis Drug Profile | 85 | 1 |
Small Molecules to Inhibit Nucleoside Hydrolase for Leishmaniasis Drug Profile | 86 | 1 |
Synthetic Peptides for Infectious Disease Drug Profile | 87 | 1 |
Vaccine for Leishmaniasis Drug Profile | 88 | 1 |
visceral leishmaniasis vaccine Drug Profile | 89 | 1 |
Leishmaniasis (Kala-Azar) Dormant Projects | 90 | 2 |
Leishmaniasis (Kala-Azar) Discontinued Products | 92 | 1 |
Leishmaniasis (Kala-Azar) Product Development Milestones | 93 | 8 |
Featured News &Press Releases | 93 | 1 |
Dec 15, 2015: U.S. Issues Patent on Corifungin | 93 | 1 |
Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program | 93 | 1 |
Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions | 93 | 1 |
Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients | 94 | 1 |
Feb 26, 2013: National Institutes of Health Supports Acea s Research | 95 | 1 |
Mar 06, 2012: 10 million boost for neglected tropical disease research at Dundee | 95 | 1 |
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis | 96 | 1 |
Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS | 97 | 1 |
Jul 01, 2011: FDA issues orphan-drug designation to Corifungin | 98 | 1 |
Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status | 98 | 1 |
Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC | 99 | 1 |
Dec 14, 2005: Collaboration on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis | 99 | 2 |
Appendix | 101 | 2 |
Methodology | 101 | 1 |
Coverage | 101 | 1 |
Secondary Research | 101 | 1 |
Primary Research | 101 | 1 |
Expert Panel Validation | 101 | 1 |
Contact Us | 101 | 1 |
Disclaimer | 102 | 1 |